Powered by
GRAND RAPIDS–Cancer & Hematology Centers of Western Michigan has launched a cancer drug repository program to accept qualified unused oral cancer drug donations from individuals so they can be used …
LAKELAND–Abionyx Pharma reported that the pilot Phase 2a clinical trial evaluating its drug candidate CER-001, the only natural recombinant apoA-I, as a treatment for septic patients at high risk of …
PLYMOUTH—Esperovax, the Plymouth developer of oral mRNA biologics, and Boston-based Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a partnership to …
ANN ARBOR—Evoq Therapeutics Inc., the Ann Arbor-based immune disease drug development firm, and Foster City, Calif.-based Gilead Sciences Inc. (Nasdaq: GILD) have announced a collaboration and licensing agreement to advance …
PLYMOUTH—Esperovax, a Plymouth-based developer of oral vaccines, announced a new, exclusive licensing agreement with Innovation Partners at the University of Michigan to produce vaccines and therapeutics using a novel yeast-based …
ANN ARBOR–CareEvolution has announced a membership with the Decentralized Trials & Research Alliance (DTRA) to collaborate in the efforts to improve global adoption and education surrounding decentralized research, participant-centric trial …
WIXOM–Rockwell Medical Inc. (Nasdaq: RMTI), the Wixom-based developer of products for patients suffering from blood and kidney disorders, announced it would suspend develop of new pharmaceutical products, and concentrate instead …
ANN ARBOR—Esperion Therapeutics Inc. (Nasdaq: ESPR) has sold 32,142,858 additional shares of its common stock to the public for $225 million, before deducting underwriting discounts, commissions, and other offering expenses. …
CANTON TWP.—MMS Holdings, the contract research organization for the pharmaceutical industry, announced the hiring of Kevin Chartier as principal advisor of biostatistics and submissions planning.Chartier will work with the biostatistics …
ANN ARBOR—Esperion Therapeutics Inc. (Nasdaq: ESPR), developers of a new class of cholesterol-lowering drugs, announced a 40 percent work force reduction and said it would focus its marketing efforts more …